BioVie Inc. Secures $4.74 Million in Registered Direct Offering
PRIVATENov 06, 2026
Amount Raised
$4.74 Million
Round Type
Post-IPO Equity
BiotechnologyHealth CareTherapeuticsBiopharma
Description
On November 3, 2026, BioVie Inc. entered into a securities purchase agreement with an institutional investor to raise approximately $4.74 million through a registered direct offering. The offering included shares of Class A common stock and pre-funded warrants. The gross proceeds will be utilized for working capital and corporate purposes.
Who to call at BioVie, and when
A new round usually means BioVie is about to hire and buy. The teams that reach out first get the meeting.
An alert the day BioVie raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at BioVie, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at BioVie. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
BioVie
About
BioVie Inc. is a biopharmaceutical company focused on the development of therapies for chronic liver diseases and cognitive disorders. The company aims to address critical unmet medical needs with innovative solutions. They leverage advanced technology and research to create impactful treatments.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment BioVie raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
